Home Industries Market Insights About Us Publisher Contact us

Cardiac Biomarker Diagnostic Kits Market By Type (Creatine Kinase (CK-MB), Troponins T And I, Myoglobin, B-Type Natriuretic Peptide (BNP), N-Terminal Prob-Type Natriuretic Peptide (NT-Probnp), Ischemia-Modified Albumin (IMA), And Others), Product (Reagents and Kits, Instruments, Chemiluminescence, Immunofluorescence, Elisa, and Immunochromatography), Disease (Myocardial Infarction, Congestive Heart Failure) - Global Opportunity Analysis And Industry Forecast, 2021-2027

Categories: Life Science

Formate :

Introduction

The global Cardiac Biomarker Diagnostic Kits market is predicted to grow at a CAGR of 11.3 percent (2019 to 2026), from $7,635 million in 2018 to $18,230 million in 2026. A biomarker or biological marker is a quantifiable pointer of some organic state or condition. Biomarkers are regularly estimated and assessed to analyze typical organic, pathogenic, or pharmacologic reactions to a remedial intervention. 

 

Biomarkers are utilized in numerous logical fields. Diagnostic Kit implies an item containing reagents and different things essential to direct a test to recognize the presence of or to quantify a given Biomarker in a given Patient Sample. Biomarkers used for medication, or accuracy medicine, are a part of a relatively new clinical toolset. A biomarker can be any particle demonstrating the presence, past or present, of living beings. 

 

Cardiac Biomarker Diagnostic Kits are requested to help identify the presence of ACS and heart ischemia and to assess their seriousness. Increments in at least one heart biomarker in the blood can distinguish individuals with ACS or cardiovascular ischemia, permitting quick and exact conclusion and suitable treatment of their condition. In geography and astrobiology, biomarkers versus geo markers are otherwise called biosignatures. 

 

Cardiac Biomarker Diagnostic Kits Market Dynamics

Key development drivers remember the rise in the quantity of new cardiovascular cases analyzed every year and increment popular for explicit ailment treatment in which heart biomarkers are utilized. Therefore, expanding the predominance of cardiovascular sicknesses is required to help the Cardiac Biomarker Diagnostic Kits market soon. 

 

Cardiac markers are biomarkers estimated to assess heart work. They can be helpful in the early forecast or determination of illness. Even though they are regularly examined regarding dead myocardial tissue, different conditions can prompt a rise in heart marker level. 

 

A biomarker diagnostic alludes to an organic boundary that guides the determination of sickness and may decide infection movement and therapy achievement. It might be a research facility, radiological, hereditary, anatomical, and physiological, or other findings that assist with separating one ailment from others. 

 

Presently, natriuretic peptides are the most commonly used biomarkers and aid in diagnosing and prognosis patients with heart failure. Although it makes sense for patients to check natriuretic peptide values at discharge, their role in treatment monitoring remains controversial.

 

Cardiac Biomarker Diagnostic Kits Application

In the medicinal sector, diagnostic tests are used to discover and analyze diseases such as heart condition, whether to approve the diagnosis of an illness or remove the likely disease causes of the patient's illness.

 

Biomarker diagnostics are critical in the ideal, precise analysis and the board of extreme coronary condition just as the visualization. Heart biomarkers are likewise a fantastic asset for triaging. Among the numerous biomarkers, the soonest inspected were the myocardial catalysts, a few myocardial proteins, peptides, and numerous articles. The most recent expansion to the collection is the microRNAs, which are steady particles recognizable available for use.

 

Based on logical advancement, strategies for the early determination, visualization forecast, and assessment of remedial impacts ought to be created. Presently, translational exploration has gotten progressively significant. 

 

Indeed, even in fundamental exploration with creature models, it is essential to affirm the clinical hugeness is utilizing human-determined obsessive examples to create analytic instruments and treatments. Subsequently, the association of examination situations that incorporate expansive regions from essential to clinical exploration becomes progressively significant.

 

Various variables sway the development of the cardiac biomarkers market. However, a portion of the critical components is essential for evaluating different cardiovascular disorders, improvement, progression in cardiac biomarkers, and development in patients experiencing cardiovascular infections. 

 

The cardiac biomarkers market is observing restraints due to the advancement of other methods for diagnosing cardiovascular sicknesses, with the high cost of the procedure, absence of a complete proof guarantee, and sheer competition among current players.

 

Cardiac Biomarker Diagnostic Kits Market Segmentation

The market is segmented based on type, product, disease, type of testing, and region. 

 Based on type, the cardiac biomarkers market is segmented into

  • Creatine kinase(CK-MB), 
  • Troponins T and I, 
  • Myoglobin, 
  • B-type natriuretic peptide (BNP), 
  • N-terminal prob-type natriuretic peptide (NT-proBNP), 
  • Ischemia-modified albumin (IMA), and others. 

Based on product, the market is segmented into 

  • Reagents and Kits, 
  • Instruments, 
  • Chemiluminescence, 
  • Immunofluorescence, 
  • Elisa, and Immunochromatography. 

 

 Based on disease, the market is segmented into 

  • Myocardial Infarction, 
  • Congestive Heart Failure. 

 

 Based on testing type, the market is segmented into 

  • Laboratory Testing,
  • Point-Of-Care Testing. 

 

Regional Overview

North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa are examined in the cardiac biomarkers. 

 

In terms of the revenue share of the whole market, North America is expected to be the industry leader. North America is estimated to dominate the Cardiac Biomarker Diagnostic Kits market in terms of the revenue share of the total market. 

 

The significant illness burden resulting from North America's high CHD prevalence, as well as the growing popularity of point-of-care diagnostics, are projected to drive demand for cardiovascular disease diagnostics.

 

Due to its vast population of nearly 4.2 billion people and high prevalence of cardiovascular disorders, the Asia Pacific area is expected to have the quickest growth rate. Therefore, the rise of the cardiac biomarkers vertical in the Asia Pacific area is projected to be fueled by this rapid expansion.

 

Competitive Landscape

Some of the major players in the global cardiac biomarkers market are 

  • Beckman Coulter
  • bioMérieux SA
  • Philips
  • Abbott Laboratories
  • Olympus Corporation
  • Siemens Healthcare GmbH
  • Johnson and Johnson
  • Hoffmann-La Roche Ltd.
  • Tosoh Corporation
  • PerkinElmer Inc.

 

In May 2016, Philips, a Dutch multinational conglomerate corporation headquartered in Amsterdam, launched the Minicare I-20 system for cardiac troponin testing. The handheld blood test for rapid diagnosis of a heart attack.

Chapter 1 Cardiac Biomarker Diagnostic Kits Market Overview


1.1 Product Overview and Scope of Cardiac Biomarker Diagnostic Kits


1.2 Cardiac Biomarker Diagnostic Kits Market Segmentation By Type


1.2.1 Creatine Kinase (CK-MB),


1.2.2 Troponins T And I,


1.2.3 B-Type Natriuretic Peptide (BNP),


1.2.4 N-Terminal Prob-Type Natriuretic Peptide (NT-Probnp),


 


1.2.5 Ischemia-Modified Albumin (IMA)


1.3 Cardiac Biomarker Diagnostic Kits Market Segmentation by Applications


1.3.1 Reagents and Kits,


1.3.2 Instruments,


1.3.3 Chemiluminescence


1.3.4 Immunofluorescence,


1.3.5 Elisa, and Immunochromatography


1.4 Cardiac Biomarker Diagnostic Kits Market Segmentation by Regions


1.4.1 North America


1.4.2 China


1.4.3 Europe


1.4.4 Southeast Asia


1.4.5 Japan


1.4.6 India


1.5 Global Market Size (Value) of Cardiac Biomarker Diagnostic Kits (2015-2027)


 


Chapter 2 Global Economic Impact on Cardiac Biomarker Diagnostic Kits Industry


2.1 Global Macroeconomic Environment Analysis


2.1.1 Global Macroeconomic Analysis


2.1.2 Global Macroeconomic Environment Development Trend


2.2 Global Macroeconomic Environment Analysis by Regions


 


Chapter 3 Global Cardiac Biomarker Diagnostic Kits Market Competition by Manufacturers


3.1 Global Cardiac Biomarker Diagnostic Kits Production and Share by Manufacturers (2021 and 2021)


3.2 Global Cardiac Biomarker Diagnostic Kits Revenue and Share by Manufacturers (2021 and 2021)


3.3 Global Cardiac Biomarker Diagnostic Kits Average Price by Manufacturers (2021 and 2021)


3.4 Manufacturers Cardiac Biomarker Diagnostic Kits Manufacturing Base Distribution, Production Area and Product Type


3.5 Cardiac Biomarker Diagnostic Kits Market Competitive Situation and Trends


3.5.1 Cardiac Biomarker Diagnostic Kits Market Concentration Rate


3.5.2 Cardiac Biomarker Diagnostic Kits Market Share of Top 3 and Top 5 Manufacturers


3.5.3 Mergers & Acquisitions, Expansion


 


Chapter 4 Global Cardiac Biomarker Diagnostic Kits Production, Revenue (Value) by Region (2015-2021)


4.1 Global Cardiac Biomarker Diagnostic Kits Production by Region (2015-2021)


4.2 Global Cardiac Biomarker Diagnostic Kits Production Market Share by Region (2015-2021)


4.3 Global Cardiac Biomarker Diagnostic Kits Revenue (Value) and Market Share by Region (2015-2021)


4.4 Global Cardiac Biomarker Diagnostic Kits Production, Revenue, Price and Gross Margin (2015-2021)


4.5 North America Cardiac Biomarker Diagnostic Kits Production, Revenue, Price and Gross Margin (2015-2021)


4.6 Europe Cardiac Biomarker Diagnostic Kits Production, Revenue, Price and Gross Margin (2015-2021)


4.7 China Cardiac Biomarker Diagnostic Kits Production, Revenue, Price and Gross Margin (2015-2021)


4.8 Japan Cardiac Biomarker Diagnostic Kits Production, Revenue, Price and Gross Margin (2015-2021)


4.9 Southeast Asia Cardiac Biomarker Diagnostic Kits Production, Revenue, Price and Gross Margin (2015-2021)


4.10 India Cardiac Biomarker Diagnostic Kits Production, Revenue, Price and Gross Margin (2015-2021)


 


Chapter 5 Global Cardiac Biomarker Diagnostic Kits Supply (Production), Consumption, Export, Import by Regions (2015-2021)


5.1 Global Cardiac Biomarker Diagnostic Kits Consumption by Regions (2015-2021)


5.2 North America Cardiac Biomarker Diagnostic Kits Production, Consumption, Export, Import by Regions (2015-2021)


5.3 Europe Cardiac Biomarker Diagnostic Kits Production, Consumption, Export, Import by Regions (2015-2021)


5.4 China Cardiac Biomarker Diagnostic Kits Production, Consumption, Export, Import by Regions (2015-2021)


5.5 Japan Cardiac Biomarker Diagnostic Kits Production, Consumption, Export, Import by Regions (2015-2021)


5.6 Southeast Asia Cardiac Biomarker Diagnostic Kits Production, Consumption, Export, Import by Regions (2015-2021)


5.7 India Cardiac Biomarker Diagnostic Kits Production, Consumption, Export, Import by Regions (2015-2021)


 


Chapter 6 Global Cardiac Biomarker Diagnostic Kits Production, Revenue (Value), Price Trend by Type


6.1 Global Cardiac Biomarker Diagnostic Kits Production and Market Share by Type (2015-2021)


6.2 Global Cardiac Biomarker Diagnostic Kits Revenue and Market Share by Type (2015-2021)


6.3 Global Cardiac Biomarker Diagnostic Kits Price by Type (2015-2021)


6.4 Global Cardiac Biomarker Diagnostic Kits Production Growth by Type (2015-2021)


 


Chapter 7 Global Cardiac Biomarker Diagnostic Kits Market Analysis by Application


7.1 Global Cardiac Biomarker Diagnostic Kits Consumption and Market Share by Application (2015-2021)


7.2 Global Cardiac Biomarker Diagnostic Kits Consumption Growth Rate by Application (2015-2021)


7.3 Market Drivers and Opportunities


7.3.1 Potential Applications


7.3.2 Emerging Markets/Countries


 


Chapter 8 Cardiac Biomarker Diagnostic Kits Manufacturing Cost Analysis


8.1 Cardiac Biomarker Diagnostic Kits Key Raw Materials Analysis


8.1.1 Key Raw Materials


8.1.2 Price Trend of Key Raw Materials


8.1.3 Key Suppliers of Raw Materials


8.1.4 Market Concentration Rate of Raw Materials


8.2 Proportion of Manufacturing Cost Structure


8.2.1 Raw Materials


8.2.2 Labour Cost


8.2.3 Manufacturing Expenses


8.3 Manufacturing Process Analysis of Cardiac Biomarker Diagnostic Kits 


 


Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers


9.1 Cardiac Biomarker Diagnostic Kits Industrial Chain Analysis


9.2 Upstream Raw Materials Sourcing


9.3 Raw Materials Sources of Cardiac Biomarker Diagnostic Kits Major Manufacturers in 2021


9.4 Downstream Buyers


 


Chapter 10 Marketing Strategy Analysis, Distributors/Traders


10.1 Marketing Channel


10.1.1 Direct Marketing


10.1.2 Indirect Marketing


10.1.3 Marketing Channel Development Trend


10.2 Market Positioning


10.2.1 Pricing Strategy


10.2.2 Brand Strategy


10.2.3 Target Client


10.3 Distributors/Traders List


 


Chapter 11 Market Effect Factors Analysis


11.1 Technology Progress/Risk


11.1.1 Substitutes Threat


11.1.2 Technology Progress in Related Industry


11.2 Consumer Needs/Customer Preference Change


11.3 Economic/Political Environmental Change


 


Chapter 12 Global Cardiac Biomarker Diagnostic Kits Market Forecast (2021-2027)


12.1 Global Cardiac Biomarker Diagnostic Kits Production, Revenue Forecast (2021-2027)


12.2 Global Cardiac Biomarker Diagnostic Kits Production, Consumption Forecast by Regions (2021-2027)


12.3 Global Cardiac Biomarker Diagnostic Kits Production Forecast by Type (2021-2027)


12.4 Global Cardiac Biomarker Diagnostic Kits Consumption Forecast by Application (2021-2027)


12.5 Cardiac Biomarker Diagnostic Kits Price Forecast (2021-2027)


 


Chapter 13 Appendix    


 


 

Request For Methodology

To receive a sample copy of this report, please complete the form below

Kindly share your specific requirement (if any)

Request For List Of Tables

To receive a sample copy of this report, please complete the form below

Kindly share your specific requirement (if any)

FAQ

What is Cardiac Biomarker Diagnostic Kits?

A biomarker or biological marker is a quantifiable pointer of some organic state or condition. Biomarkers are regularly estimated and assessed to analyze typical organic, pathogenic, or pharmacologic reactions to a remedial intervention.

What is the current size of the global Cardiac Biomarker Diagnostic Kits market?

The global Cardiac Biomarker Diagnostic Kits market is predicted to grow at a CAGR of 11.3 per cent (2019 to 2026) from $7,635 million in 2018 to $18,230 million in 2026.

Which region is projected to account for the largest share in the Cardiac Biomarker Diagnostic Kits market?

In terms of the revenue share of the whole market, North America is expected to be the industry leader. North America is estimated to dominate the Cardiac Biomarker Diagnostic Kits market in terms of the revenue share of the total market.

What are the Top companies in Cardiac Biomarker Diagnostic Kits Market?

Beckman Coulter, bioMérieux SA, Philips, Abbott Laboratories, Olympus Corporation, Siemens Healthcare GmbH, Johnson and Johnson, F. Hoffmann-La Roche Ltd., Tosoh Corporation, PerkinElmer Inc.

What are the segmentation of Cardiac Biomarker Diagnostic Kits Market?

The market is segmented based on type, product, disease, type of testing, and region.

What are the application of Cardiac Biomarker Diagnostic Kits?

In the medicinal sector, diagnostic tests are used to discover and analyze diseases such as heart condition, whether it is to approve the diagnosis of a disease or remove the likely disease causes of the patient's illness.

Choose License Type

Single User

US$ 3500

Multi User

US$ 5250

Corporate User

US$ 7000

Personalize this Research

  • Market Size and Share from 2016 - 2027
  • Expected Market Growth Until 2027
  • COVID-19 Impact assessment on the market
  • Market Dynamics and Impact Analysis
  • Segment and region that will drive or lead the market growth and why
  • Industry activity comprising Mergers, Acquisitions, Expansion, etc.
  • Comprehensive Mapping of the Competitive Landscape
  • In-depth analysis of key sustainability strategies adopted by market players
  • Global and regional market trends – Current and Future
  • Value Chain Analysis
  • Porters Five Forces Analysis
  • Historical and Current Product Pricing
  • Country Cross-Segment Analysis
  • Company Profiling
  • Player Comparison Matrix

Life Science Clients

Cardiac Biomarker Diagnostic Kits Market By Type (...

RD Code : HP22